Search This Blog

Friday, March 13, 2026

bioAffinity Technologies 2026 outlook for more than 100% growth in CyPath Lung test volumes

 


  • Reported 2025 results with record CyPath Lung performance, including an 87% jump in product revenue.
Posted by at

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.

Subscribe to: Post Comments (Atom)